Results 221 to 230 of about 381,851 (298)

Glyco‐Nanogels for Modulating Pseudomonas aeruginosa Biofilm

open access: yesMacromolecular Rapid Communications, EarlyView.
Nanogels presenting α‐galactose and β‐fucose can significantly alter Pseudomonas aeruginosa biofilm dynamics through their interaction with lectins. Application timing is crucial: pre‐treatment reduces biofilm, while treatment after biofilm initiation increases biomass.
Sophia Rosencrantz   +4 more
wiley   +1 more source

Opioid Prescribing for Hand Surgery: A Medicare Part D Analysis. [PDF]

open access: yesHand (N Y)
Zhang J   +7 more
europepmc   +1 more source

Clinical Progression in Alpha‐Synuclein Positive LRRK2‐PD and Sporadic Parkinson's Disease: A Longitudinal Analysis

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background LRRK2‐Parkinson's disease (LRRK2‐PD) is biologically heterogeneous with approximately 30% lacking aggregated alpha synuclein (αSyn) in cerebrospinal fluid by seed amplification assay (SAA). Prior work has suggested slower progression in LRRK2‐PD compared to sporadic PD (sPD).
Lucy A. Morse   +224 more
wiley   +1 more source

Annotation and characterization of lesions in breast tomosynthesis images. [PDF]

open access: yesRadiat Prot Dosimetry
Dustler M   +6 more
europepmc   +1 more source

Continuous Apomorphine Infusion in Multiple System Atrophy Real‐World Insights From a French Nationwide Retrospective Cohort

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background Continuous subcutaneous apomorphine infusion (CSAI) is effective in Parkinson's disease but has not been evaluated in multiple system atrophy (MSA). Objective To assess the 6‐month efficacy and tolerability of CSAI in MSA patients. Methods French multicenter retrospective registry‐based analysis of CSAI use in MSA.
Simon Lamy   +16 more
wiley   +1 more source

Localized bullous pemphigoid in the setting of chronic lymphedema. [PDF]

open access: yesJAAD Case Rep
O'Connor MB   +3 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy